子宮頸がん治療の世界市場:種類別(扁平上皮がん、腺癌)、製品別(予防、治療)、流通チャネル別(オンライン、病院薬局)、セグメント予測

【英語タイトル】Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (SCC, Adenocarcinoma), By Product (Prevention, Treatment), By Distribution Channel (Online, Hospital Pharmacies), And Segment Forecasts, 2018 - 2025

Grand View Researchが出版した調査資料(GVW903047)・商品コード:GVW903047
・発行会社(調査会社):Grand View Research
・発行日:2018年12月19日
・ページ数:83
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥648,550見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥648,550見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥975,550見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、子宮頸がん治療の世界市場について調査・分析し、子宮頸がん治療の世界市場動向、子宮頸がん治療の世界市場規模、市場予測、セグメント別子宮頸がん治療市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global cervical cancer treatment market size is expected to reach USD 10.6 billion by 2025, according to a new report by Grand View Research, Inc. The market is projected to record a CAGR of 5.0% over the forecast period. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.
The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines – Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Further key findings from the study suggest:

• HPV affects nearly 95% of all cervical cancer cases. HPV strains 16 and 18 account for nearly 70% of all cases reported

• Nearly three-fourth of all cases occur in developing and underdeveloped regions (mostly, in Asia and Africa), where healthcare facilities are limited and awareness about diagnosis and treatment is low

• North America was the dominant region in the global cervical cancer treatment market and is expected to continue its dominance over the estimated period

• This growth is attributed to growing target population patient, increasing market penetration of drugs, and easy accessibility to advanced treatments

• Some of the key companies in the market include F. Hoffmann-LA Roche AG; Merck & Co., Inc.; GlaxoSmithKline PLC; Allergan PLC; Pfizer, Inc.; Biocon Ltd.; Bristol-Myers Squibb Company; AstraZeneca PLC; and Eli Lilly & Co.

• Merck & Co. led the competitive space and is likely to continue to be the largest shareholder due to strong commercial performances of Gardasil and Keytruda

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List of Tables
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
Chapter 4 Market Definitions
4.1 Disease Primer and Epidemiology
4.2 Market Segmentation
Chapter 5 Industry Outlook
5.1 Market Variable Analysis
5.1.1 High Disease Prevalence
5.1.2 Proactive governmnet initiatives
5.1.3 Availability of targeted therapies
5.1.4 Increase in R&D funding for cancer research
5.2 Market Restraint Analysis
5.2.1 Lack of consumer awareness
5.2.2 High cost of treatment
Chapter 6 Business Environment Analysis
6.1 SWOT Analysis; By factor (political & legal, economic and technological)
6.2 Porter’s Five Forces Analysis
6.3 Pipeline Analysis
Chapter 7 Type Business Analysis
7.1 Cervical Cancer Treatment market: Type Movement Analysis
7.2 Squamous Cell Carcinoma
7.2.1 Squamous Cell Carcinoma market estimates and forecast, 2014 – 2025
7.3 Adenocarcinoma
7.3.1 Adenocarcinoma market estimates and forecast, 2014 – 2025
7.4 Adenosquamous Carcinoma
7.4.1 Adenosquamous Carcinoma market estimates and forecast, 2014 – 2025
Chapter 8 Product Business Analysis
8.1 Cervical Cancer Treatment market: Product Movement Analysis
8.2 Gardasil/Gardasil 9
8.2.1 Gardasil/Gardasil 9 market estimates and forecast, 2014 – 2025
8.3 Cervarix
8.3.1 Cervarix market estimates and forecast, 2014 – 2025
8.4 Avastin
8.4.1 Avastin market estimates and forecast, 2014 – 2025
8.5 Keytruda
8.5.1 Keytruda market estimates and forecast, 2014 – 2025
8.6 Generics
8.6.1 Generics market estimates and forecast, 2014 – 2025
8.7 Others
8.7.1 others market estimates and forecast, 2014 – 2025
Chapter 9 Distribution Channel Business Analysis
9.1 Cervical Cancer Treatment market: Distribution Channel Movement Analysis
9.2 Hospital Pharmacies
9.2.1 Hospital pharmacies market estimates and forecast, 2014 – 2025
9.3 Retail Pharmacies
9.3.1 Retail pharmacies market estimates and forecast, 2014 – 2025
9.4 Online Pharmacies
9.4.1 Online pharmacies market estimates and forecast, 2014 – 2025
Chapter 10 Regional Business Analysis
10.1 Cervical Cancer Treatment Market: Regional Movement Analysis
10.2 North America
10.2.1 North America market estimates and forecast, 2014 – 2025
10.2.2 U.S.
10.2.2.1 U.S. market estimates and forecast, 2014 – 2025
10.2.3 Canada
10.2.3.1 Canada market estimates and forecast, 2014 – 2025
10.3 Europe
10.3.1 Europe market estimates and forecast, 2014 – 2025
10.3.2 Germany
10.3.3 Germany market estimates and forecast, 2014 – 2025
10.3.4 UK
10.3.5 UK market estimates and forecast, 2014 – 2025
10.4 Asia-Pacific
10.4.1 Asia-Pacific market estimates and forecast, 2014 – 2025
10.4.2 Japan
10.4.2.1 Japan market estimates and forecast, 2014 – 2025
10.4.3 China
10.4.3.1 China market estimates and forecast, 2014 – 2025
10.4.4 India
10.4.4.1 India market estimates and forecast, 2014 – 2025
10.5 Latin America
10.5.1 Latin America market estimates and forecast, 2014 – 2025
10.5.2 Brazil
10.5.2.1 Brazil market estimates and forecast, 2014 – 2025
10.5.3 Mexico
10.5.3.1 Market estimates and forecast, 2014 – 2025
10.6 Middle East and Africa
10.6.1 Middle-East and Africa market estimates and forecast, 2014 – 2025
10.6.2 South Africa
10.6.3 South Africa market estimates and forecast, 2014 – 2025
Chapter 11 Company Profile
11.1 Company Profiles
11.1.1 F.Hoffmann-LA Roche AG
11.1.1.1 Company overview
11.1.1.2 Financial Performance
11.1.1.3 Product benchmarking
11.1.1.4 Strategic initiatives
11.1.2 Merck & Co., Inc.
11.1.2.1 Company overview
11.1.2.2 Financial Performance
11.1.2.3 Product benchmarking
11.1.2.4 Strategic initiatives
11.1.3 GLAXOSMITHKLINE plc
11.1.3.1 Company overview
11.1.3.2 Financial Performance
11.1.3.3 Product benchmarking
11.1.3.4 Strategic initiatives
11.1.4 ALLERGAN
11.1.4.1 Company overview
11.1.4.2 Financial Performance
11.1.4.3 Product benchmarking
11.1.4.4 Strategic initiatives
11.1.5 PFIZER, Inc.
11.1.5.1 Company overview
11.1.5.2 Financial Performance
11.1.5.3 Product benchmarking
11.1.5.4 Strategic initiatives
11.1.6 BIOCON Limited
11.1.6.1 Company overview
11.1.6.2 Financial Performance
11.1.6.3 Product benchmarking
11.1.6.4 Strategic initiatives
11.1.7 Bristol-Myers Squibb
11.1.7.1 Company overview
11.1.7.2 Financial Performance
11.1.7.3 Product benchmarking
11.1.7.4 Strategic initiatives
11.1.8 AstraZeneca
11.1.8.1 Company overview
11.1.8.2 Financial Performance
11.1.8.3 Product benchmarking
11.1.8.4 Strategic initiatives
11.1.9 Eli Lilly and Company
11.1.9.1 Company Overview
11.1.9.2 . FINANCIAL PERFORMANCE
11.1.9.3 Product Benchmarking
11.1.9.4 Strategic Initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 Cervical Cancer Epidemiology - 2017
Table 3 Cervical Cancer - Pipeline Intelligence
Table 4 Product Portfolio: Gardasil
Table 5 Product Portfolio: Cervarix
Table 6 Product Portfolio: Avastin
Table 7 Product Portfolio: Keytruda
Table 8 Product Portfolio: Generics
Table 9 North America Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 10 North America Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 11 North America Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 12 U.S. Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 13 U.S. Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 14 U.S. Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 15 Canada Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 16 Canada Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 17 Canada Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 18 Europe Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 19 Europe Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 20 Europe Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 21 U.K. Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 22 U.K. Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 23 U.K. Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 24 Germany Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 25 Germany Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 26 Germany Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 27 Latin America Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 28 Latin America Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 29 Latin America Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 30 Brazil Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 31 Brazil Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 32 Brazil Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 33 Mexico Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 34 Mexico Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 35 Mexico Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 36 Asia Pacific Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 37 Asia Pacific Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 38 Asia Pacific Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 39 Japan Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 40 Japan Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 41 Japan Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 42 China Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 43 China Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 44 China Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 45 India Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 46 India Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 47 India Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 48 MEA Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 49 MEA Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 50 MEA Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)
Table 51 South Africa Cervical Cancer Market, by Type, 2014 - 2025 (USD Million)
Table 52 South Africa Cervical Cancer Market, by Product, 2014 - 2025 (USD Million)
Table 53 South Africa Cervical Cancer Market, by Distribution Channel, 2014 - 2025 (USD Million)

List of Figures

Fig. 1 Cervical cancer treatment market snapshot
Fig. 2 Cervical cancer treatment market segmentation
Fig. 3 Current disease prevalence - 2017
Fig. 4 Cervical cancer treatment market - driver impact
Fig. 5 Cervical cancer treatment market - restraint impact
Fig. 6 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 7 Porter’s Five Forces Analysis
Fig. 8 Cervical Cancer Treatment market: Type outlook and key takeaways
Fig. 9 Cervical Cancer Treatment market: Type Movement Analysis
Fig. 10 Squamous cell carcinoma market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 11 Adenocarcinoma market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 12 Adenosquamous carcinoma market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 13 Cervical Cancer Treatment market: Product outlook and key takeaways
Fig. 14 Cervical Cancer Treatment market: Product Movement Analysis
Fig. 15 Gardasil/Gardasil 9 market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 16 Cervarix market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 17 Avastin market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 18 Keytruda market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 19 Generics market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 20 Others market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 21 Cervical Cancer Treatment market: Distribution Channel outlook and key takeaways
Fig. 22 Cervical Cancer Treatment Market: Distribution Channel Movement Analysis
Fig. 23 Hospital Pharmacies market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 24 Retail Pharmacies market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 25 Online Pharmacies market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 26 Cervical Cancer Treatment Market: Regional Outlook and Key Takeaways
Fig. 27 Cervical Cancer Treatment market: Regional movement analysis
Fig. 28 North America
Fig. 29 North America. market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 30 U.S. market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 31 Canada market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 32 Europe
Fig. 33 Europe market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 34 Germany market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 35 U.K. market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 36 Asia-Pacific
Fig. 37 Asia-Pacific market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 38 Japan market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 39 China. market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 40 India market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 41 Latin America
Fig. 42 Latin America market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 43 Brazil market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 44 Mexico market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 45 Middle East & Africa
Fig. 46 MEA market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 47 South Africa market estimates and forecast, 2014 - 2025 (USD Million)
Fig. 48 Company profile

【掲載企業】

F.Hoffmann-LA Roche AG、Merck & Co., Inc.、GLAXOSMITHKLINE plc、ALLERGAN、PFIZER, Inc.、BIOCON Limited、Bristol-Myers Squibb、AstraZeneca、Eli Lilly and Company

★調査レポート[子宮頸がん治療の世界市場:種類別(扁平上皮がん、腺癌)、製品別(予防、治療)、流通チャネル別(オンライン、病院薬局)、セグメント予測] (コード:GVW903047)販売に関する免責事項を必ずご確認ください。
★調査レポート[子宮頸がん治療の世界市場:種類別(扁平上皮がん、腺癌)、製品別(予防、治療)、流通チャネル別(オンライン、病院薬局)、セグメント予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆